Biography
William K. Oh, M.D., is currently the Director of Precision Medicine at Yale Cancer Center and a Professor of Medicine (Medical Oncology) at Yale School of Medicine, roles he assumed in October 2024. As part of a newer initiative at Yale, he is focused on building a cohesive program in precision cancer medicine that integrates basic and translational science, clinical trials, and Smilow Cancer Hospital’s Precision Medicine Tumor Board. A central goal of his work is to increase the routine use of molecular and genetic testing for all cancer patients to improve outcomes. Dr. Oh is also dedicated to delivering multidisciplinary care for prostate cancer patients, a priority he has maintained for over 25 years. He has been recognized as a Top Doctor by Castle Connolly, New York Magazine, and Super Doctors. Additionally, he continues his commitment to teaching and advancing research in the field. Previously, Dr. Oh was a Clinical Professor of Medicine at Icahn School of Medicine. He is an internationally recognized medical oncologist with extensive experience in clinical and translational research, holding leadership roles in both academia and industry. He has authored more than 350 articles, reviews, books, and book chapters related to genitourinary cancers. Dr. Oh has conducted numerous clinical cancer trials and served in key invited roles for ASCO, ACS, and AUA. He has also held the position of Chief Medical Officer for Sema4, a genomics and health intelligence company, as well as the Prostate Cancer Foundation.

Biography
Dr. Kurzrock is a boardcertified medical oncologist and a renowned expert in precision medicine. She developed one of the worlds largest Phase I clinical trial programs while at MD Anderson Cancer Center. Dr. Kurzrock also founded the UCSDs Center for Personalized Cancer Therapy, focusing on genomicallydriven therapy as well as precision immunotherapy, especially in rare cancers. Dr. Kurzrock brought the first transcriptomic study to the clinic in an international setting spanning five countries (WINTHER), as well as the first Nof1 study of individually customized combination therapy (IPREDICT). Dr. Kurzrock received her MD from the University of Toronto, Canada. She has 900 PubMed publications, an Hindex of 140, has been named to the lists of most highly cited scientists in the world. She has a uniquely strong record of competitive funding with 100 million dollars in lifetime funding, and has overseen early development of multiple drugs that are now FDA approved.

Biography
Dr. Hedvig Hricak, a diagnostic radiologist, served from 1999 to January 2023 as Chair of the Department of Radiology of Memorial Sloan Kettering Cancer Center, where she remains on the faculty, is a Member of the Molecular Pharmacology Program, Sloan Kettering Institute and is Professor, Gerstner Sloan Kettering Graduate School of Biomedical Sciences. She has made pioneering contributions to genitourinary cancer imaging, and her publications include over 380 peer-reviewed research articles, over 300 review articles, editorials, and book chapters, and 18 books. She has been a leader in promoting implementation of precision imaging in oncology, integrated diagnostics, and cancer engineering. She is also devoted to reducing global disparities in cancer care and chaired the steering committee of The Lancet Oncology Commission on Medical Imaging and Nuclear Medicine. Her numerous awards include the David Rall Medal for Distinguished Leadership from the National Academy of Medicine, of which she is a member.

Talk
Imaging plays essential roles in evaluating cancers biological diversity, spatial complexity, and evolution over time. This lecture will focus on recently established and emerging advances in imaging that have the capacity to improve cancer outcomes and survival in the era of precision oncology.

Biography
Dr. Kishore Pillarsetty is a highly trained and respected radiochemist who heads the Targeted Theranostics Laboratory at Memorial Sloan Kettering Cancer Center . He holds a Ph.D. in chemistry and has 25 years experience in developing radiopharmaceuticals. His research program is focused on developing novel radiotheranostics for applications in cancer and neurodegeneration. Towards this, his laboratory develops novel radiochemical methods and novel radiolabeled compounds and comprehensively evaluates their in vivo performance in animal models and translates them to clinic. He has 95 peer reviewed publications, 10 patent applications, and has aided clinical translation of 10 PET probes. He has presented his groundbreaking findings at various national and international conferences, including serving as plenary speaker. Owing to his prominence and expertise in his field, he is sought after and actively serves in several internal and external committees, task forces, including SNMMI, WMIC, NTAP, NIH to promote, advocate, and expand the use of radiopharmacetucials.

Biography
As Head of Digital Oncology, Ashley leads the Varian ARIA CORE product family, Eclipse treatment planning, the Patient Engagement Platform, Noona, InSightive Analytics, and the interoperability tools that bring the Varian software ecosystem together. Ashley is passionate about bringing tools to clinicians that can help them enhance the care they provide cancer patients around the world. Over the course of her 18-year career at Varian, Ashley has held various roles within commercial sales leadership across North America and Asia Pacific. In 2019, Ashley transitioned to an RD position leading the Varian ARIA CORE suite of products. Prior to joining Varian, Ashley was co-founder and President of Oncology Plus, a chemotherapy compounding pharmacy servicing the Southeastern United States which she sold to a multi-national group in 2015. Ashley studied biology and chemistry at Florida State University and holds a master's degree in organizational management.

Biography
Dr. Marshall Pitz is a medical oncologist and clinical investigator at CancerCare Manitoba and an Associate Professor of Internal Medicine at the Max Rady College of Medicine, University of Manitoba. He specializes in neuro-oncology and breast cancer, focusing on clinical trials and outcomes research to improve treatments.Dr. Pitz leads a $1.5 million Canadian Cancer Society-funded clinical trial to test new treatments for low-survival brain cancers. This trial, in collaboration with the Australian Cooperative Trials Group for Neuro-Oncology, aims to personalize treatments based on the molecular profile of the cancer.Dr. Pitz holds a Master of Health Science in Clinical Investigation from Johns Hopkins Bloomberg School of Public Health and an MD from the University of Manitoba. He has received several awards, including the Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award.

Biography
Thomas Hope, MD is a radiologist and nuclear medicine physician. He is the Vice Chair of Clinical Operations and Strategy in the Department of Radiology, and serves as the Director of Molecular Therapy. Dr. Hopes main research focus is on novel imaging agents and therapies, particularly in prostate cancer and neuroendocrine tumors. He lead the development of Ga-68 PSMA-11, which subsequently led to the approval of this drug by the FDA. He has combined his interest in MR imaging with PET in the simultaneous modality PETMRI, helping lead the development of the clinical PETMRI program. Additionally he leads the PRRT (peptide receptor radionuclide therapy) program for neuroendocrine tumors and PSMA Radioligand Therapy at UCSF.

Biography
Christian is responsible for driving business development and incubation in adjacent fields and white spaces at Siemens Healthineers. Christian and his team evaluate opportunities, trigger investments in start-ups, and drive partnership projects with a particular focus on the field of precision medicine. Christian also serves on the board of associations and start-up companies focusing on precision medicine. Christian brings more than 15 years of experience in new business development and has successfully incubated a variety of new products, developed strategies for leading global companies, and is the (co)-inventor of assorted patent families. He is driven by his passion to bridge the chasm between innovative ideas and the commercialization of new technologies.

Biography
Dr. Hedvig Hricak, a diagnostic radiologist, served from 1999 to January 2023 as Chair of the Department of Radiology of Memorial Sloan Kettering Cancer Center, where she remains on the faculty, is a Member of the Molecular Pharmacology Program, Sloan Kettering Institute and is Professor, Gerstner Sloan Kettering Graduate School of Biomedical Sciences. She has made pioneering contributions to genitourinary cancer imaging, and her publications include over 380 peer-reviewed research articles, over 300 review articles, editorials, and book chapters, and 18 books. She has been a leader in promoting implementation of precision imaging in oncology, integrated diagnostics, and cancer engineering. She is also devoted to reducing global disparities in cancer care and chaired the steering committee of The Lancet Oncology Commission on Medical Imaging and Nuclear Medicine. Her numerous awards include the David Rall Medal for Distinguished Leadership from the National Academy of Medicine, of which she is a member.

Biography
Dr. Jones Nauseef is a board-certified medical oncologist and physician scientist with expertise in prostate cancer genomics, management, and clinical trials. At Convergent Therapeutics, he has driven clinical development and the initiation of the phase II CONVERGE-01 trial. Following his PhD in Molecular Physiology and Biophysics, he completed his Internal Medicine and Medical Oncology training at Weill Cornell Medicine (WCM) and remained to serve as an Assistant Professor and member of the Englander Institute for Precision Medicine and the Meyer Cancer Centers Experimental Therapeutics program. He contributed to the design and execution of anti-PSMA radiopharmaceutical trials (e.g., 225Ac-J591). He has served as a key opinion leader on genitourinary therapeutics and participated in national collaborative consortia. Beyond PSMA, his research focus included the genomics of African-ancestry prostate cancers and on advanced, non-adenocarcinoma prostate tumors. He maintains a courtesy affiliation with WCM and a research collaboration with the New York Genome Center.

Biography
Dr. Bien-Willner is the Medical Director of the MolDX program at Palmetto GBA, a Medicare Administrative Contractor (MAC). He is a leader in the Precision Medicine space and practices as a Board-certified Anatomic Pathologist and Molecular Genetic Pathologist. Throughout his career, he has been active in research, development, and advancement of molecular diagnostic services, specifically next generation sequencing. He has worked closely with clinicians to develop clear clinical diagnostic and treatment pathways directing Precision Medicine programs for community cancer centers. Dr. Bien-Willner received his MD and PhD degrees from Baylor College of Medicine, with a PhD in Human Molecular Genetics. He completed his residency, fellowship, and attained a faculty appointment at Washington University in St. Louis prior to leadership roles in laboratory and biotech companies before joining Palmetto GBA.

Biography
Sheila D. Walcoff is a nationally recognized FDA policy expert who advises precision medicine companies and investors on LDTIVD regulatory strategy, FDA submissions, and application of FDAISO quality systems to CLIA laboratories. She is CEO and founder of Goldbug Strategies, which provides clinical, regulatory, quality systems, and PCCP consulting for LDTs, IVDs, pharmaCDx, and AIdigital health technologies. In addition to many successful FDA submissions, including firstofakind LDTIVDs, Sheilas 25+ years experience includes FDA associate commissioner, U.S. HHS senior science public health official, BigLaw partner, congressional committee counsel, and entrepreneur. She earned her J.D. at Georgetown University Law Center.

Biography
Sharmila Majumdar, Ph.D., obtained her Ph.D. degree from Yale University inEngineering and Applied Sciences. After a short stay at Yale she joinedUCSF as an Assistant Professor in 1989. Her research on machine and deeplearning has a focus on imaging; prior work has focused on imagingtechnology development and translational, development of image processing,computer vision has been focused in the areas of osteoporosis,osteoarthritis, and lower back pain. She is the Executive and ScientificDirector of the Center for Intelligent Imaging at UCSF. She was selected asa fellow of the American Institute of Medical and Biological Engineers in2004, a fellow of the International Society of Magnetic Resonance inMedicine (ISMRM) in 2008, and awarded the ISMRM Gold medal in 2016. She isan active participant in the PMWC meetings. Her work over the last threedecades has been extensively supported by the NIH and industry.

Biography
Dr. Hedvig Hricak, a diagnostic radiologist, served from 1999 to January 2023 as Chair of the Department of Radiology of Memorial Sloan Kettering Cancer Center, where she remains on the faculty, is a Member of the Molecular Pharmacology Program, Sloan Kettering Institute and is Professor, Gerstner Sloan Kettering Graduate School of Biomedical Sciences. She has made pioneering contributions to genitourinary cancer imaging, and her publications include over 380 peer-reviewed research articles, over 300 review articles, editorials, and book chapters, and 18 books. She has been a leader in promoting implementation of precision imaging in oncology, integrated diagnostics, and cancer engineering. She is also devoted to reducing global disparities in cancer care and chaired the steering committee of The Lancet Oncology Commission on Medical Imaging and Nuclear Medicine. Her numerous awards include the David Rall Medal for Distinguished Leadership from the National Academy of Medicine, of which she is a member.

Biography
Dr. Eliot Siegel is a renowned radiologist and innovator in the fields of medical imaging and informatics. He is Professor of Radiology and Nuclear Medicine at the University of Maryland School, where he leads groundbreaking research in artificial intelligence (AI) applications in radiology. He currently serves as founder and of United Theranostics, a national Nuclear Medicine practice specializing in radiopharmaceutical therapy for clinical trials and patient care. He created the National Cancer Imaging Archive as lead for the caBIG medical imaging program, served as Chair of the SPIE Medical Imaging conference and currently co-chairs a national conference on Machine Intelligence in Medical Imaging. Dr. Siegel developed and implemented the worlds first Picture Archiving and Communication Systems (PACS). His work bridges clinical practice, cutting-edge research, and informatics, making significant contributions to healthcare systems and academic institutions. His leadership in medical imaging has earned him recognition at both national and international levels.

Biography
Dr. Michael E. Phelps is globally recognized for his pioneering contributions to the field of medical imaging, particularly for inventing the Positron Emission Tomography (PET) scanner. His discoveries and inventions with his colleagues and students have enabled PETCT and PETMRI to revolutionize the diagnosis and treatment of a wide range of diseases, including cancer, neurological disorders, and cardiovascular disease. By providing images and measures of biological processes of disease at the molecular level, PET has transformed the way physicians and scientists understand, diagnosis and treat disease, making personalized care more precise and effective.Dr. Phelps founded and Chaired the Department of Molecular Medical Pharmacology that uniquely integrated faculty from the biological physical sciences with MDPhDs and MDs from imaging, Medicine Surgery, and contained the academic and clinical service of Nuclear Medicine in the David Geffen School of Medicine at UCLA. He was one the 3 founders of CTI Molecular Imaging that after reaching a market cap of $2B in 2005, was acquired by Siemens. More recently, he is one of the founders and a board member of Sofie Biosciences. Dr. Phelps is a member of the National Academy of Science and the National Academy of Medicine.

Biography
Dr. Michael E. Phelps is globally recognized for his pioneering contributions to the field of medical imaging, particularly for inventing the Positron Emission Tomography (PET) scanner. His discoveries and inventions with his colleagues and students have enabled PETCT and PETMRI to revolutionize the diagnosis and treatment of a wide range of diseases, including cancer, neurological disorders, and cardiovascular disease. By providing images and measures of biological processes of disease at the molecular level, PET has transformed the way physicians and scientists understand, diagnosis and treat disease, making personalized care more precise and effective.Dr. Phelps founded and Chaired the Department of Molecular Medical Pharmacology that uniquely integrated faculty from the biological physical sciences with MDPhDs and MDs from imaging, Medicine Surgery, and contained the academic and clinical service of Nuclear Medicine in the David Geffen School of Medicine at UCLA. He was one the 3 founders of CTI Molecular Imaging that after reaching a market cap of $2B in 2005, was acquired by Siemens. More recently, he is one of the founders and a board member of Sofie Biosciences. Dr. Phelps is a member of the National Academy of Science and the National Academy of Medicine.

Biography
Wafik El-Deiry is a practicing physician-scientist and medical oncologist at Brown University who sees patients with colorectal cancer and is a translational-oncology investigator focused on cell death, cancer drug resistance, new cancer drugs, and precision oncology. Dr. El-Deiry is one of a handful of people in the world who discovered a cancer suppressor (TRAIL receptor DR5), discovered a drug that activates this cancer suppressive molecular and cellular pathway, ONC201TIC10 (Dordaviprone), founded the company that licensed the drug (Oncoceutics, Inc. acquired by Chimerix, Inc. in 2021), and the drug is in process towards FDA approval in 2025 for shrinking aggressive brain tumors. In 2023, Dr. El-Deiry was named as Top Doctor in Oncology in Pennsylvania and Rhode Island and was elected Chair of Worldwide Innovative Network (WIN)-Consortium in Personalized Cancer Medicine. He was elected as a Senior Member of the National Academy of Inventors in 2024.

Biography
Tuvik is a seasoned entrepreneur and experienced executive, who spent the last twenty years building, scaling, and leading AI-driven companies in healthcare, life sciences and other domains. He is a co-founder and board member of MedAware, a leader in AI patient safety solutions, and CEO of Pangea Biomed, developing advanced predictive biomarkers for oncology. He holds a BSc in mathematics from Tel Aviv University and a PhD in computational neuroscience from the Hebrew University.

Biography
Wui-Jin Koh, MD, is the Senior Vice PresidentChief Medical Officer at the National Comprehensive Cancer Network (NCCN). In this role, Dr. Koh helps oversee the flagship NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) program. In addition, he is responsible for medical leadership and oversight for NCCNs continuing medical education program, and represents the organization at clinical and scientific meetings. Prior to his role at NCCN, he served as Professor of Radiation Oncology at University of Washington and Medical Director for Radiation Oncology at Fred Hutchinson Cancer Research CenterSeattle Cancer Care Alliance. Dr. Koh earned his medical degree at Loma Linda University School of Medicine. He conducted his post-graduate training at the University of Washington Medical Center, completing a residency and internship in radiation oncology and a clinical fellowship in tumor imaging. He is board-certified in radiation oncology.

Biography
Marija Plodinec is a recognized industry leader and opinion leader in the physical sciences of oncology, with a strong scientific and industry presence in the U.S. and Europe. For over a decade, Marija has launched the development of ARTIDIS, a groundbreaking medical device leveraging nanomechanical signatures for fast and precise diagnosis and treatment optimization of solid tumors. As co-founder, CEO, and Board Member of ARTIDIS AG since 2017, she has led the company through significant growth milestones. Thanks to her leadership and extensive network with key U.S. industry leaders, particularly at MD Anderson Cancer Center, ARTIDIS established a U.S. subsidiary and a strategic alliance collaboration that has positioned the company for rapid growth in the American market.

Talk

Biography
At Ultima Genomics, our mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health.To achieve this, we built a revolutionary new sequencing architecture that scales far beyond conventional technologies, enabling scientists to overcome the tradeoffs they face between the breadth, depth and frequency of sequencing.

Biography
Luca Quagliata is the Vice President and Global Head of Medical Affairs for Thermo Fisher's Clinical Sequencing and Oncology Division. He's also a Venture Partner at xGEN VC-Fund, and serves on the boards of ACMA and IQNPath. Previously, he held key positions at the University Hospital of Basel.

Biography
Dr. Kurzrock is a boardcertified medical oncologist and a renowned expert in precision medicine. She developed one of the worlds largest Phase I clinical trial programs while at MD Anderson Cancer Center. Dr. Kurzrock also founded the UCSDs Center for Personalized Cancer Therapy, focusing on genomicallydriven therapy as well as precision immunotherapy, especially in rare cancers. Dr. Kurzrock brought the first transcriptomic study to the clinic in an international setting spanning five countries (WINTHER), as well as the first Nof1 study of individually customized combination therapy (IPREDICT). Dr. Kurzrock received her MD from the University of Toronto, Canada. She has 900 PubMed publications, an Hindex of 140, has been named to the lists of most highly cited scientists in the world. She has a uniquely strong record of competitive funding with 100 million dollars in lifetime funding, and has overseen early development of multiple drugs that are now FDA approved.

Biography
Dr. Ibiayi Dagogo-Jack, is a thoracic oncologist at Massachusetts General Hospital and an Assistant Professor of Medicine at Harvard Medical School. She specializes in the treatment of lung cancer, with a focus on advanced disease, targeted therapies, and immunotherapies. As a clinician investigator, Dr. Dagogo-Jacks research is dedicated to understanding and overcoming resistance to therapy in thoracic malignancies.Her work combines cutting-edge research with compassionate patient care, aiming to optimize outcomes for patients through personalized medicine. Dr. Dagogo-Jack has authored numerous peer-reviewed publications in leading journals and is frequently invited to speak at national and international conferences on topics such as precision oncology and novel therapeutic strategies.Dr. Dagogo-Jack earned her medical degree from the University of Chicago Pritzker School of Medicine and completed her residency in internal medicine at Brigham and Women's hospital, followed by a fellowship in hematologyoncology at the Dana-FarberHarvard Cancer Center.

Biography
Stacey Tinianov is a patient advocate and the founder and executive director of Advocates for Collaborative Education, a non-profit organization dedicated to uniting advocates through pan-cancer collaborations, basic and advanced advocacy education, and the sharing of leading practices across patient, research, and policy advocacy.As an early stage breast cancer survivor, Stacey's personal experiences with the healthcare system deeply inform her advocacy efforts and she draws on career experience in education, communications and training, technology, operations, and strategic planning to help elevate patient, community, research, and policy advocacy; build bridges between science, industry, policy, and communities; and to co-create methods of delivering accessible, quality, person-centered care. Stacey has a Masters of Public Health from The Milken Institute School of Public Health at George Washington University.

Biography
Dr. Krupa Paranjpe is a distinguished leader in oncology with expertise in global stakeholder engagement, medical affairs strategy, and clinical innovation. As the Global Stakeholder Relations Lead at Sanofi Oncology, she plays a pivotal role in shaping collaborative strategies that address health system barriers, evolve oncology endpoints, and advance diagnostic approaches such as minimal residual disease (MRD) testing.With a strong focus on improving patient outcomes, Dr. Paranjpe drives initiatives that bridge clinical research, diagnostics, and real-world application. Her experience spans impactful programs such as the OncoCollective Initiative, where she has championed innovative solutions to meet the unmet needs in cancer care.Dr. Paranjpe earned her Doctor of Pharmacy (Pharm.D.) degree and has since built a career dedicated to addressing critical challenges in oncology through collaboration and innovation.

Talk
Key Points: -Transformational importance of evolving endpoints in oncology-MRD in Multiple Myeloma-A collective of multi-disciplinary oncology experts focus on addressing Health System barriers in adoption of MRD as an endpoint-Educationawareness for all stakeholders in ecosystem: Patients, Providers, payers, regulators

Biography